GenScript Signs Worldwide Non-Exclusive License Agreement with TransGenic

GenScript has made a worldwide (excluding Japan) non-exclusive license agreement with TransGenic for utilizing the GANP (Germinal Center Associated Nuclear Protein) technology in the development of antibodies with high affinity.

Dr. Nobuo Sakaguchi at Kumamoto University discovered the GANP protein. The protein is highly expressed in the embryo’s B-cells. Studies have revealed that the GANP protein plays a major role in the restoration of antibody genes. Transgenic mice expressing elevated GANP levels can be utilized to develop high-affinity antibodies.

David Chang, Director of GenScript’s Antibody Department, has stated that the GANP technology will significantly enhance specificity, affinity and epitope diversity attributes of their antibody products.

GenScript has built a sophisticated antibody production platform to cope with their clients’ demands like OptimumAntigenTM design tool, T-MaxTM adjuvant and nanotechnology for antigen production. The animal facility of the company is AAALAC and OLAW certified. The antibodies developed using the GANP technology can be utilized for several analytic and treatment purposes due to improved affinity and enhanced specificity.

Source: http://www.genscript.com